Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Anterior Chamber XEN Gel Stent Movements

The Impact on Corneal Endothelial Cell Density

Gillmann, Kevin, FEBOphth, MBBS, M.Arch*; Bravetti, Giorgio E., MD*; Mermoud, André, MD*; Mansouri, Kaweh, MD, MPH*,†

doi: 10.1097/IJG.0000000000001200
Online Articles: Case Report/Small Case Series
Buy

Introduction: Although there are several examples of glaucoma drainage devices’ dislocations in the literature, the movement of XEN gel stents is scarcely documented, and the impact of such displacements on the corneal endothelium remains unknown. In light of the recent global market withdrawal of the CyPass microstent over concerns with regard to endothelial cell loss, we present a case of XEN gel stent dislocation into the anterior chamber, with localized corneal damage.

Case Report: We describe the case of a 64-year-old female patient who underwent bilateral XEN gel stent implantation for normal-tension glaucoma. While right eye surgery was uneventful, intraocular pressure increased in the left eye, and examination revealed a flat filtration bleb with no microstent visible through the conjunctiva. A 3 mm segment of the XEN stent was visible within the anterior chamber, with corneal contact during eye movement and blinking. Endothelial cell density was measured twice 1 month apart before the XEN gel stent was replaced.

Discussion: First, our observations confirm that XEN gel stents can dislocate and advance within the anterior chamber. We speculate that this displacement was caused by regular eye rubbing after surgery. Second, this report illustrates that the position of a drainage device within the anterior chamber is dynamic and significantly influenced by eye movements and blinking. Finally, occasional corneal contact of a XEN gel stent can cause a reduction in endothelial cell density of 2.1% in a month, which represents 46.2% of the annual endothelial loss observed by Tan and colleagues in patients with a Baerveldt tube (4.54% annual decrease).

*Glaucoma Research Centre, Monchoisi Clinic, Swiss Visio Network, Lausanne, Switzerland

Department of Ophthalmology, University of Colorado School of Medicine, Denver, CO

Supported in part by the Swiss Glaucoma Research Foundation, Lausanne.

Disclosure: K.M.: Santen (C), Sensimed (C), Topcon (S), Alcon (S), Allergan (S), Optovue (S), ImplanData (C). A.M.: Alcon (S), Allergan (S), Santen (C), Swiss Advanced Vision (C), Rheon Medical (C), Glaukos (C), Diopsys Inc. (C), DeepCube (C). The remaining authors declare no conflict of interest.

Reprints: Kaweh Mansouri, MD MPH, Glaucoma Research Center, Montchoisi Clinic, Chemin des Allinges 16, 1006 Lausanne, Switzerland (e-mail: kwmansouri@gmail.com).

Received December 1, 2018

Accepted January 6, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.